Modality
Vaccine
MOA
EGFRi
Target
PD-L1
Pathway
Innate Imm
Ewing SarcomaHSPsA
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
~Dec 2017
→ ~Mar 2019
Phase 2
Jun 2019
→ Jul 2027
Phase 2Current
NCT04629718
2,548 pts·Ewing Sarcoma
2019-09→2027-07·Not yet recruiting
NCT06844566
2,466 pts·Ewing Sarcoma
2019-06→TBD·Active
5,014 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-07-271.3y awayPh2 Data· Ewing Sarcoma
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2
Active
P2
Not yet…
Catalysts
Ph2 Data
2027-07-27 · 1.3y away
Ewing Sarcoma
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04629718 | Phase 2 | Ewing Sarcoma | Not yet recr... | 2548 | FEV1 |
| NCT06844566 | Phase 2 | Ewing Sarcoma | Active | 2466 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| 207-2754 | Samsung Biologics | Phase 1/2 | KRASG12D | |
| Mavuratamab | Blueprint Medicines | NDA/BLA | BET | |
| Bemaderotide | Revolution Medicines | Phase 3 | BCL-2 |